Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1027.

https://doi.org/10.1182/blood-2023-181762

Published: 2023

Journal Articles

Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians

Rawan Atallah, Md Saiful Islam Saif, Danai Dima, Anuj Shrestha, Faiz Anwer, Muhammad Umair Mushtaq, Forat Lutfi, Leyla Shune, Hamza Hashmi, Siddhartha Ganguly, Joseph P McGuirk, Shebli Atrash, Al-Ola Abdallah, Rahul Banerjee, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6678.

https://doi.org/10.1182/blood-2023-181218

Published: 2023

Journal Articles

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Blood (2023) 142 (Supplement 1): 355.

https://doi.org/10.1182/blood-2023-181181

Published: 2023

Journal Articles

Long Term Follow up of Elderly Patients with Classical Hodgkin's Lymphoma: An Analysis of the Texas Cancer Registry

Ethan A. Burns, Sunil Mathur, Darshil Choksi, Hala Hassanain, Yuqi Zhang, Cesar Gentille Sanchez, Ryan B. Kieser, Carrie Yuen, Shilpan S. Shah, Siddhartha Ganguly, Sai Ravi Kiran Pingali

Blood (2022) 140 (Supplement 1): 3687–3688.

https://doi.org/10.1182/blood-2022-159777

Published: 2022

Journal Articles

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Blood (2022) 140 (Supplement 1): 4636–4638.

https://doi.org/10.1182/blood-2022-169452

Published: 2022

Journal Articles

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Blood (2022) 139 (9): 1330–1339.

https://doi.org/10.1182/blood.2021013289

Published: 2022

Includes: Supplemental data

Journal Articles

Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM)

Ethan A. Burns, Joe E. Ensor, Kartik Anand, Cesar Gentille, Carlo Guerrero, Ryan B. Kieser, Godsfavor Umoru, Shilpan S. Shah, Jenny H. Petkova, Siddhartha Ganguly, Lawrence Rice, Sai Ravi Kiran Pingali

Blood (2021) 138 (Supplement 1): 4740.

https://doi.org/10.1182/blood-2021-152068

Published: 2021

Journal Articles

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction

Frederick L. Locke, Caron Jacobson, Long Ma, Hua Dong, Zhen-Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David B. Miklos, Yi Lin, Miguel-Angel Perales, Matthew A. Lunning, Megan M. Herr, Brian T. Hill, Siddhartha Ganguly, Abu-Sayeef Mirza, Sarah Nikiforow, Hairong Xu, Marcelo C Pasquini

Blood (2021) 138 (Supplement 1): 530.

https://doi.org/10.1182/blood-2021-149679

Published: 2021

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL)

Blood (2021) 138 (Supplement 1): 3880.

https://doi.org/10.1182/blood-2021-148652

Published: 2021

Journal Articles

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

Blood (2021) 137 (23): 3291–3305.

https://doi.org/10.1182/blood.2020009362

Published: 2021

Includes: Supplemental data

Journal Articles

Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis

Blood (2021) 137 (4): 556–568.

https://doi.org/10.1182/blood.2020006252

Published: 2021

Includes: Supplemental data

Journal Articles

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

David S. Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD FRCPC, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD FRCPC, Christopher S. Seet, MD PhD, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand M. Anz, III, MD, Gustavo A. Fonseca, MD, Donna E. Reece, MD, Kim Lee, Weiyuan Chung, Amit Agarwal, MD PhD, Nizar J. Bahlis, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134189

Published: 2020

Journal Articles

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Caitlin L. Costello, MD, Adam D. Cohen, MD, Krina K. Patel, MD, Syed S Ali, MD, Jesus G. Berdeja, MD, Nina Shah, MD, Siddhartha Ganguly, MD, Mehmet Hakan Kocoglu, MD, Mehrdad Abedi, MD, Eric M. Ostertag, MD PhD, Chris E Martin, PhD, Majid Ghoddussi, PhD, Devon J Shedlock, PhD, Joanne McCaigue, M.S., Hamid Namini, PhD, Sreeni Yalamanchili, Matthew A. Spear, MD, Tara K. Gregory, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142695

Published: 2020

Journal Articles

Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Hematological Malignancies: Insights from the National Inpatient Sample

Ghulam Rehman Mohyuddin, MD, Kellen Gil, Brian McClune, Nausheen Ahmed, Al-Ola Abdallah, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Leyla Shune, MD, Saqib Abbasi

Blood (2020) 136 (Supplement 1): 53–54.

https://doi.org/10.1182/blood-2020-142978

Published: 2020

Journal Articles

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Youngsook Choi, MD, Jeanne Mendell, PhD MPH, Ruth Namuyinga, MD MPH, Hoang Pham, PharmD, Nabil Said, MD MPH, Yibin Wang, PhD, Tsvetomir Mitov, MD, Ben Kim, PharmD, Samer K. Khaled, MD

Blood (2019) 134 (Supplement_1): 1372.

https://doi.org/10.1182/blood-2019-121762

Published: 2019

Journal Articles

Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

Sudhakiranmayi Kuravi, M.S., Janice Cheng, MD, Kishore Polireddy, PhD, Gabrielle Fangman, B.S., Roy A Jensen, MD, Tara L. Lin, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Ramesh Balusu, PhD

Blood (2019) 134 (Supplement_1): 2865.

https://doi.org/10.1182/blood-2019-130633

Published: 2019

Journal Articles

Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Samer K. Khaled, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Marc Botteman, MS, MA, Ruchit Shah, PhD, Linlin Luo, MSc, Zhenming Shun, PhD, Saurabh Ray, PhD

Blood (2019) 134 (Supplement_1): 382.

https://doi.org/10.1182/blood-2019-123554

Published: 2019

Journal Articles

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Barry S. Skikne, MD, Anurag K. Singh, MD, Sunil Abhyankar, MD, Tara L. Lin, MD, Leyla Shune, MD, Neil Dunavin, MD, Ajoy L. Dias, MD, Brian McClune, DO, Abdulraheem Yacoub, MD, Clint Divine, Haitham Abdelhakim, MD, Siddhartha Ganguly, MD, Jennifer Hanses, Carol E Webb, BA, Joseph P. McGuirk, DO

Blood (2019) 134 (Supplement_1): 5743.

https://doi.org/10.1182/blood-2019-130828

Published: 2019

Journal Articles

Characterization of Response and Transfusion Independence in Patients with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory Acute Myeloid Leukemia Treated with Quizartinib or Salvage Chemotherapy in the Quantum-R Trial

Mark J. Levis, MD, Siddhartha Ganguly, MD, Samer K. Khaled, MD, Alwin Krämer, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Youngsook Choi, MD, Arnaud Lesegretain, Jeanne Mendell, PhD MPH, Derek E. Mires, PharmD, Yufen Zhang, PhD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 2599.

https://doi.org/10.1182/blood-2019-124491

Published: 2019

Journal Articles

Maintenance and Consolidation Regimens after a Second Autologous Transplant for Multiple Myeloma: A Decade of Experiences

Ghulam Rehman Mohyuddin, MD, Maire Okoniewski, Osama Diab, MD, Siddhartha Ganguly, MD, Al-Ola Abdallah, MD, Leyla Shune, MD, Joseph P. McGuirk, DO, Brian McClune, DO

Blood (2019) 134 (Supplement_1): 5700.

https://doi.org/10.1182/blood-2019-130619

Published: 2019

NARROW

Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Long Term Follow up of Elderly Patients with Classical Hodgkin's Lymphoma: An Analysis of the Texas Cancer Registry

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM)

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction

Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL)

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Hematological Malignancies: Insights from the National Inpatient Sample

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Characterization of Response and Transfusion Independence in Patients with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory Acute Myeloid Leukemia Treated with Quizartinib or Salvage Chemotherapy in the Quantum-R Trial

Maintenance and Consolidation Regimens after a Second Autologous Transplant for Multiple Myeloma: A Decade of Experiences

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only